Pfizer raised its sales forecast for the COVID-19 vaccine, which was jointly developed with Germany’s BioNTech, to $ 33.5 billion on Wednesday, up 28.8%. According to the company, vaccine sales forecasts are based on 2.1 billion contracts this year.